Compare ADMA Biologics Inc (ADMA) vs CarMax, Inc (KMX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs CarMax, Inc — how do they compare? ADMA Biologics Inc trades at $9.22 (market cap $2.13B), while CarMax, Inc trades at $50.67 (market cap $7.24B). The key difference: CarMax, Inc is far larger — about 3.4× ADMA Biologics Inc's market cap, and CarMax, Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | KMX | |
|---|---|---|
Market Cap | $2.13B | $7.24B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $68.38 |
52-Week Low | $7.60 | $30.88 |
Enterprise Value | $2.20B | $25.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
CarMax (KMX) trades at $51.05, up 0.14% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported Q1 2026 earnings that beat expectations, with revenue growth and cost control supporting a net income margin of 0.84%. Recent news highlights insider buying and a four-pillar turnaround strategy under new CEO Keith Barr, though margins remain under pressure.
The outlook is mixed: analyst consensus is cautious with a hold-heavy rating and $48.91 price target below current levels, but improving cash flow and strategic initiatives offer potential upside. Key risks include persistent margin compression, high debt levels, and execution challenges in a competitive used car market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →
